APA (7th ed.) Citation

Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, & Galsky M. (2019). Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. Dove Medical Press.

Chicago Style (17th ed.) Citation

Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, and Galsky M. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. Dove Medical Press, 2019.

MLA (9th ed.) Citation

Kongnakorn T, et al. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. Dove Medical Press, 2019.